Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with Sunitinib and resection of residual metastases

Author(s): Rini BI, Shaw V, Rosenberg, Kim ST, Chen I


A complete response (CR) to therapy in patients with metastatic renal cell carcinoma (RCC) is rare but has been achieved in a minority of patients using high-dose interleukin-2. Surgical CR after partial response to immunotherapy in metastatic RCC has been anecdotally reported, although the low overall response rate to cytokines precludes this procedure in the majority of patients. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Clinical efficacy has been demonstrated, with high objective response rates observed in a variety of solid tumor types, including RCC. Herein, we report 2 cases of patients with cytokine-refractory metastatic RCC who received sunitinib and achieved sufficient decrease in tumor burden to permit subsequent surgical resection, resulting in long-term CR.

Similar Articles

Survival and prognostic stratification of 670 patients with advanced renal cell carcionma

Author(s): Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al.

Nivolumab versus Everolimus in advanced renal-cell carcinoma

Author(s): Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al.

Immunomodulatory activity of Nivolumab in metastatic renal cell carcinoma

Author(s): Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, et al.

DNA mismatch repair genes in renal cell carcinoma

Author(s): Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, et al.

Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors

Author(s): Altavilla G, Fassan M, Busatto G, Orsolan M, Giacomelli L

Mismatch repair gene mutations in renal cell carcinoma

Author(s): Leach FS, Koh M, Sharma K, McWilliams G, Talifero-Smith L, et al.

PD-1 blockade in tumors with mismatch-repair deficiency

Author(s): Le D, Uram J, Wang H, Bartlett BR, Kemberling H, et al.

Mismatch repair-deficient cancers are targets for anti-PD-1 therapy

Author(s): Kelderman S, Schumacher TN, Kvistborg P